CJC-1295 NO DAC (5 mg Vial)

CJC-1295 NO DAC Research Chart

CJC-1295 NO DAC has been studied in scientific research related to peptide mechanisms and biological pathways. Research findings may vary depending on study design, methodology, and experimental conditions.

CJC-1295 NO DAC (also known as Modified GRF 1–29 or Mod GRF) is a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog. It is studied for its ability to stimulate the body’s natural, pulsatile release of growth hormone from the pituitary gland. Unlike direct growth hormone administration, CJC-1295 NO DAC is designed to support the body’s normal hormonal signaling pathways. Research suggests it may help promote healthy growth hormone (GH) and IGF-1 activity while maintaining the body’s natural hormone release patterns. Preclinical and limited clinical research has explored its potential to support body composition, recovery, sleep quality, lean muscle maintenance, and metabolic function. This protocol outlines a once-daily subcutaneous administration approach using a practical dilution designed to provide clear and consistent insulin syringe measurements.

Educational guide for research information and scientific background.

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Phase	Daily Blend (mg)	Units	Volume (mL)
Weeks 1–2	0.6 mg	36 units	0.36 mL
Weeks 3–4	1.2 mg	72 units	0.72 mL
Weeks 5–6	2.4 mg	144 units	1.44 mL
Weeks 7–16 (Maintenance)	4.5 mg	270 units	2.70 mL

Research Information: Research measurement methods and laboratory procedures may vary depending on study design, methodology, and experimental requirements.

Reconstitution Steps

1. Draw 3.0 mL of bacteriostatic water using a sterile syringe.
2. Research Preparation Information: Laboratory preparation methods may vary depending on study design, research requirements, and approved scientific procedures.
3. Gently swirl or roll the vial until the powder has completely dissolved. Do not shake the vial.
4. Label the vial with the reconstitution date and store it refrigerated at 2–8 °C (35.6–46.4 °F), protected from direct light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–12 week daily protocol with gradual titration.

A concise overview of the once-daily CJC-1295 NO DAC protocol.

Goal: Support the body's natural pulsatile growth hormone (GH) release and healthy IGF-1 activity to promote body composition, recovery, and overall metabolic function.
Research Information: Research studies may evaluate different timeframes and experimental approaches depending on study design, methodology, and laboratory requirements.
Research Information: Research studies may evaluate different parameters depending on study design, methodology, and experimental conditions.
Research Information: Research materials and experimental conditions may vary depending on study design, methodology, and laboratory requirements.
Research Information: Research material storage considerations may vary depending on laboratory standards, study requirements, and experimental conditions.

A suggested daily titration approach for the planned protocol.

Research Information: Research studies may evaluate different parameters depending on study design, methodology, and experimental conditions.
Research Information: Research methodologies and experimental parameters may vary depending on study design, scientific objectives, and laboratory requirements.
Research Information: Research studies may evaluate different parameters depending on study design, methodology, and experimental conditions.
Research Information: Research methodologies and experimental parameters may vary depending on study design, scientific objectives, and laboratory requirements.
Cycle Length: Standard protocol is 8–12 weeks, with an optional extension to 16 weeks.
Research Information: Research methodologies and experimental approaches may vary depending on study design, scientific objectives, and laboratory requirements.

Proper storage helps maintain peptide stability and quality.

Lyophilized Vials: Store at 2–8 °C (35.6–46.4 °F). For extended storage, keep frozen at ≤ −20 °C (≤ −4 °F). Minimize exposure to moisture.
Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 1–2 weeks. Avoid repeated freeze–thaw cycles.
Before Opening: Allow the vial to reach room temperature before opening to help minimize condensation inside the vial.

Practical considerations for consistency and tolerability.

Research Information: Laboratory research procedures should follow appropriate scientific standards, safety practices, and approved methodologies.
Research Information: Scientific studies may evaluate different methodologies and approaches depending on research objectives, laboratory requirements, and experimental conditions.
Research Information: Research findings and observations may vary depending on study design, methodology, and experimental conditions.
Research Information: Scientific research may involve documentation and evaluation methods that vary depending on study design, research objectives, and laboratory procedures.
Research Information: Research methodologies and laboratory requirements may vary depending on study design, experimental conditions, and approved procedures.

CJC-1295 NO DAC (Modified GRF 1–29) is a synthetic growth hormone-releasing hormone (GHRH) analog designed with amino acid modifications that improve its stability and resistance to enzymatic breakdown. It works by binding to GHRH receptors on pituitary cells, helping stimulate the body’s natural, pulsatile release of growth hormone (GH). Unlike direct growth hormone administration, CJC-1295 NO DAC is intended to support the body’s normal hormonal signaling and feedback mechanisms, promoting a more natural pattern of GH release. Because of its relatively short duration of action, CJC-1295 NO DAC is studied for its ability to produce discrete GH pulses that more closely resemble the body’s normal physiological secretion pattern. Note: Current evidence is based primarily on preclinical research and limited human studies. Additional clinical research is needed to further evaluate the safety and effectiveness of CJC-1295 NO DAC.

The following observations are based on preclinical research and limited clinical studies of GHRH analogs.

Complementary strategies for optimal outcomes.

Pair with a balanced, protein‑forward diet tailored to individual energy needs.
Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
Prioritize adequate sleep (7–9 hours) and stress management for adherence and recovery.
Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.

Scientific research information based on published literature and established research methodologies.

Research Information: Scientific studies follow specific laboratory procedures and safety standards based on approved research methodologies.
Research Information: Scientific research procedures and methodologies may vary depending on study design, laboratory requirements, and approved experimental protocols.
Research Information: Scientific research procedures may vary depending on study design, laboratory requirements, and approved methodologies.
Research Information: Scientific studies may evaluate different methodologies and approaches depending on research objectives, laboratory requirements, and experimental conditions.

We recommend Vitality Labs Peptides for high‑purity CJC-1295 NO DAC (5 mg).

Why Vitality Labs Peptides?

This content is for educational purposes only and is not medical advice.

Wikipedia

Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics

Journal of Clinical Endocrinology & Metabolism (2006)

— Teichman et al.: Prolonged stimulation of GH and IGF‑I by CJC-1295 in healthy adults

American Journal of Physiology (2006)

— Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice

Journal of Clinical Endocrinology & Metabolism (2006)

— Veldhuis et al.: Pulsatile GH secretion persists during continuous CJC-1295 stimulation

PMC

Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels

PMC

Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity

PMC

— Sermorelin: a better approach to management of adult‑onset growth hormone insufficiency

PMC

Beyond the androgen receptor: role of GHS in body composition in hypogonadal males

PMC

The Safety and Efficacy of Growth Hormone Secretagogues (Review)

PMC

GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging

PubMed

Sermorelin: review of its use in diagnosis and treatment of GH deficiency

CDC

Vaccine administration: subcutaneous route (angle/site; no aspiration)

CDC Scientific Research Reference (Subcutaneous Methods)

— Scientific Research Reference: Subcutaneous Methods and Research Information

NCBI Bookshelf

Scientific Research Information on Laboratory Procedures and Methodology

Scientific Research Review on Subcutaneous Methods (PMC)

— Pharmacologic considerations of the subcutaneous route

Vitality Labs Peptides

CJC-1295 NO DAC Research Information and Scientific Background

CJC-1295 NO DAC (5 mg Vial)

CJC-1295 NO DAC Research Chart

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Why Vitality Labs Peptides?

Wikipedia

Journal of Clinical Endocrinology & Metabolism (2006)

American Journal of Physiology (2006)

Journal of Clinical Endocrinology & Metabolism (2006)

PMC

PMC

PMC

PMC

PMC

PMC

PubMed

CDC

CDC Scientific Research Reference (Subcutaneous Methods)

NCBI Bookshelf

Scientific Research Review on Subcutaneous Methods (PMC)

Vitality Labs Peptides

CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Research Protocol

Retatrutide (30 mg Vial) Research Protocol

Vilon (20 mg Vial) Research Protocol

Ara-290 (16 mg Vial) Research Protocol

What Is Cagrilintide? Mechanism, Benefits, Risks, and Comparisons